Mendel Jansen

607 total citations
18 papers, 474 citations indexed

About

Mendel Jansen is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mendel Jansen has authored 18 papers receiving a total of 474 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 7 papers in Molecular Biology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mendel Jansen's work include Cancer Treatment and Pharmacology (7 papers), HER2/EGFR in Cancer Research (4 papers) and Cancer therapeutics and mechanisms (3 papers). Mendel Jansen is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), HER2/EGFR in Cancer Research (4 papers) and Cancer therapeutics and mechanisms (3 papers). Mendel Jansen collaborates with scholars based in United Kingdom, United States and Japan. Mendel Jansen's co-authors include W. Ilias, Dale E. Shuster, Alain C. Mita, Eric K. Rowinsky, Christopher DesJardins, Fang Fang, Quincy S. Chu, Sanjay Goel, Sridhar Mani and Monica Mita and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Journal of Controlled Release.

In The Last Decade

Mendel Jansen

18 papers receiving 455 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mendel Jansen United Kingdom 10 166 122 93 80 65 18 474
Xiao Zhou China 12 84 0.5× 173 1.4× 204 2.2× 24 0.3× 33 0.5× 30 463
King Leung Fung United States 10 349 2.1× 34 0.3× 204 2.2× 9 0.1× 74 1.1× 13 608
Ana Miranda Portugal 11 159 1.0× 63 0.5× 158 1.7× 42 0.5× 48 0.7× 26 597
Junjun Wang China 10 142 0.9× 79 0.6× 213 2.3× 41 0.5× 43 0.7× 34 530
Huirong Huang China 14 72 0.4× 50 0.4× 211 2.3× 39 0.5× 52 0.8× 23 550
Guorong Hu China 10 193 1.2× 83 0.7× 175 1.9× 13 0.2× 37 0.6× 13 605
Kiyoko Takemiya Japan 9 35 0.2× 111 0.9× 179 1.9× 8 0.1× 141 2.2× 15 562
Karel J. Lambert United States 9 154 0.9× 109 0.9× 119 1.3× 35 0.4× 86 1.3× 10 463

Countries citing papers authored by Mendel Jansen

Since Specialization
Citations

This map shows the geographic impact of Mendel Jansen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mendel Jansen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mendel Jansen more than expected).

Fields of papers citing papers by Mendel Jansen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mendel Jansen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mendel Jansen. The network helps show where Mendel Jansen may publish in the future.

Co-authorship network of co-authors of Mendel Jansen

This figure shows the co-authorship network connecting the top 25 collaborators of Mendel Jansen. A scholar is included among the top collaborators of Mendel Jansen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mendel Jansen. Mendel Jansen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Terranova, Nadia, Mendel Jansen, Martin Falk, & Bart S. Hendriks. (2020). Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types. Cancer Chemotherapy and Pharmacology. 87(2). 185–196. 19 indexed citations
2.
Moore, Kathleen N., Johanna C. Bendell, Patricia LoRusso, et al.. (2018). First-in-human study of the anti-HB-EGF antibody U3-1565 in subjects with advanced solid tumors. Investigational New Drugs. 37(1). 147–158. 6 indexed citations
3.
Jansen, Mendel, Steve Warrington, Victor Dishy, et al.. (2018). A Randomized, Placebo‐Controlled, Double‐Blind Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeated Doses of Mirogabalin in Healthy Asian Volunteers. Clinical Pharmacology in Drug Development. 7(6). 661–669. 20 indexed citations
4.
Jansen, Mendel, Jeanne Mendell, Alexander Currie, et al.. (2018). Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Mirogabalin When Coadministered With Lorazepam, Zolpidem, Tramadol, or Ethanol: Results From Drug‐Drug Interaction Studies in Healthy Subjects. Clinical Pharmacology in Drug Development. 7(6). 597–612. 10 indexed citations
5.
Jansen, Mendel, Domenico Merante, Alexander Currie, et al.. (2016). (403) Co-administration of mirogabalin and zolpidem in healthy subjects: results from a randomized, double-blind, drug-drug interaction study. Journal of Pain. 17(4). S75–S75. 1 indexed citations
6.
Jansen, Mendel, et al.. (2016). Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors. Cancer Chemotherapy and Pharmacology. 77(5). 987–996. 5 indexed citations
7.
Ciprotti, Marika, Reimar Abraham, Mendel Jansen, et al.. (2016). A phase I, open label, two part, safety and tolerability study of U3-1784 in patients with advanced solid tumours.. Journal of Clinical Oncology. 34(15_suppl). TPS2593–TPS2593. 2 indexed citations
8.
9.
Moore, Kathleen N., Johanna C. Bendell, Anthony J. Olszanski, et al.. (2013). Phase I, first-in-human, open-label, dose-escalation study of U3-1565, a fully human anti-HB-EGF monoclonal antibody, in patients with advanced solid tumors.. Journal of Clinical Oncology. 31(15_suppl). 2519–2519. 1 indexed citations
10.
Riggs, Matthew, Takako Shimizu, Fumihiko Okada, et al.. (2013). An Evaluation of Calcilytic Effects on Parathyroid Hormone and Bone Mineral Density Response Using a Physiologically-Based, Multiscale Systems Pharmacology Model. 4 indexed citations
11.
Keizer, Ron J., Anubha Gupta, Melvin R. Mac Gillavry, et al.. (2010). A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080. Journal of Pharmacokinetics and Pharmacodynamics. 37(4). 347–363. 57 indexed citations
12.
Goel, Sanjay, Alain C. Mita, Monica Mita, et al.. (2009). A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies. Clinical Cancer Research. 15(12). 4207–4212. 121 indexed citations
13.
Jansen, Mendel, Nan Soon Wong, Mario Campone, et al.. (2009). Population pharmacokinetics (PPK) of eribulin mesylate in patients with locally advanced or metastatic breast cancer (MBC). Journal of Clinical Oncology. 27(15_suppl). 2524–2524. 5 indexed citations
14.
Keizer, Ron J., Miren Zamacona, Mendel Jansen, et al.. (2008). Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820. Investigational New Drugs. 27(2). 140–152. 21 indexed citations
15.
Nemunaitis, John, Neil Senzer, Razelle Kurzrock, et al.. (2008). Phase I dose-escalation study of E7080, a multikinase inhibitor, in patients with advanced solid tumors. Journal of Clinical Oncology. 26(15_suppl). 14583–14583. 15 indexed citations
16.
Jansen, Mendel, Ian A. Darby, Thierry Abribat, et al.. (2004). Pulmonary delivery of TH9507, a growth hormone releasing factor analogue, in the dog. International Journal of Pharmaceutics. 276(1-2). 75–81. 11 indexed citations
17.
Jansen, Mendel, et al.. (2003). Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs. Journal of Controlled Release. 91(3). 385–394. 123 indexed citations
18.
Ilias, W. & Mendel Jansen. (1996). PAIN CONTROL AFTER HYSTERECTOMY: AN OBSERVER‐BLIND, RANDOMISED TRIAL OF LORNOXICAM VERSUS TRAMADOL. International Journal of Clinical Practice. 50(4). 197–202. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xiao Zhou Breakdown of academic impact, for papers by King Leung Fung Breakdown of academic impact, for papers by Ana Miranda Breakdown of academic impact, for papers by Junjun Wang Breakdown of academic impact, for papers by Huirong Huang Breakdown of academic impact, for papers by Guorong Hu Breakdown of academic impact, for papers by Kiyoko Takemiya Breakdown of academic impact, for papers by Karel J. Lambert
Rankless by CCL
2026